Search results for "high [electromagnetic field]"

showing 10 items of 20620 documents

The potential role of mitochondrial ATP synthase inhibitory factor 1 (IF1) in coronary heart disease: a literature review

2017

Cardiovascular disease (CVD) is the leading cause of death worldwide, and so the search for innovative and accurate biomarkers for guiding prevention, diagnosis, and treatment is a valuable clinical and economic endeavor. Due to a recent findings that the serum concentration of mitochondrial ATP synthase inhibitory factor 1 (IF1) is an independent prognostic factor in patients with coronary heart disease (CHD), we reviewed the role of this protein in myocardial ischemic preconditioning, its correlation to plasma high density lipoprotein (HDL), the predictive potential in patients with CHD, and its interplay with angiogenesis. IF1 has been positively correlated with plasma HDL-cholesterol, a…

0301 basic medicinemedicine.medical_specialtyClinical chemistryAngiogenesisEndocrinology Diabetes and MetabolismInhibitory factor 1Clinical BiochemistryHigh density lipoproteinCoronary DiseaseClinical nutritionDiseaseReview030204 cardiovascular system & hematologyBioinformaticsMitochondrial Proteins03 medical and health scienceschemistry.chemical_compoundAngiogenesis; Cardiovascular disease; High density lipoprotein; Inhibitory factor 10302 clinical medicineEndocrinologyHigh-density lipoproteinInternal medicineMedicineHumansCause of deathBiochemistry medicalbiologybusiness.industryBiochemistry (medical)ProteinsCardiovascular diseaseMitochondria030104 developmental biologyEndocrinologychemistrybiology.proteinIschemic preconditioningApolipoprotein A1AngiogenesisbusinessLipids in Health and Disease
researchProduct

Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures

2019

Summary Guidance is provided in an international setting on the assessment and specific treatment of postmenopausal women at low, high and very high risk of fragility fractures. Introduction The International Osteoporosis Foundation and European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis published guidance for the diagnosis and management of osteoporosis in 2019. This manuscript seeks to apply this in an international setting, taking additional account of further categorisation of increased risk of fracture, which may inform choice of therapeutic approach. Methods Clinical perspective and updated literature search. Results The following areas are reviewed: …

0301 basic medicinemedicine.medical_specialtyFRAXEndocrinology Diabetes and MetabolismeducationOsteoporosisPsychological interventioninhibitors of bone resorption030209 endocrinology & metabolismRisk AssessmentAnabolic agents03 medical and health sciencesTherapeutic approach0302 clinical medicineBone DensityRisk FactorsTreatment of osteoporosisInternal medicinemedicinefracture risk assessmentHumansanabolic agentsIntensive care medicineOsteoporosis PostmenopausalAgedAnabolic agents Fracture risk assessment FRAX Inhibitors of bone resorption Treatment of osteoporosisddc:616Postmenopausal womenbusiness.industryCorrectionFracture risk assessmentInhibitors of bone resorptionMiddle Agedtreatment of osteoporosismedicine.diseaseRheumatologyIncreased riskFemalePosition Paper030101 anatomy & morphologybusinessVery high riskAlgorithmsOsteoporotic FracturesFRAXOsteoporosis International
researchProduct

European Guidelines (S1) on the use of high‐dose intravenous immunoglobulin in dermatology

2016

Background The treatment of severe dermatological autoimmune diseases and toxic epidermal necrolysis (TEN) with high-dose intravenous immunoglobulin (IVIg) is a well-established procedure in dermatology. As treatment with IVIg is usually considered for rare clinical entities or severe clinical cases, the use of immunoglobulin is not generally based on data from randomized controlled trials that are usually required for the practice of evidence-based medicine. Owing to the rarity of the indications for the use of IVIg, it is also unlikely that such studies will be available in the foreseeable future. Because the high costs of IVIg treatment also limit its first-line use, the first clinical g…

0301 basic medicinemedicine.medical_specialtyMEDLINEHigh dose intravenous immunoglobulin610 Medicine & healthEuropean Guidelines (S1) high-dose intravenous immunoglobulinDermatologySkin DiseasesDrug Administration Schedulelaw.inventionAutoimmune Diseases2708 Dermatology030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineRandomized controlled triallawhemic and lymphatic diseasesintravenous immunoglobulinmedicineHumanshigh-doseEvidence-Based MedicineDose-Response Relationship Drugbusiness.industryDermatological diseases10177 Dermatology ClinicImmunoglobulins Intravenous2725 Infectious DiseasesEvidence-based medicinemedicine.diseaseDermatologyToxic epidermal necrolysisEuropeInfectious Diseases030104 developmental biologyEuropean Guidelines (S1)Dermatology clinicStevens-Johnson SyndromeInjections IntravenousEuropean Guidelines (S1) high-dose intravenous immunoglobulin dermatologyDrug MonitoringbusinessJDDG: Journal der Deutschen Dermatologischen Gesellschaft
researchProduct

Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society …

2021

International audience; Background and aimsThis European Atherosclerosis Society (EAS) Task Force provides practical guidance for combination therapy for elevated low-density lipoprotein cholesterol (LDL-C) and/or triglycerides (TG) in high-risk and very-high-risk patients.MethodsEvidence-based review.ResultsStatin-ezetimibe combination treatment is the first choice for managing elevated LDL-C and should be given upfront in very-high-risk patients with high LDL-C unlikely to reach goal with a statin, and in primary prevention familial hypercholesterolaemia patients. A proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor may be added if LDL-C levels remain high. In high and very-h…

0301 basic medicinemedicine.medical_specialtyStatinSettore MED/09 - Medicina InternaCombination therapymedicine.drug_classHigh-risk2019 ESC/EAS Dyslipidaemia GuidelineLipid goal030204 cardiovascular system & hematologyTriglyceride03 medical and health sciences0302 clinical medicineCombined treatmentcardiovascular diseaseInternal medicinemedicineHumanstriglycerides2019 ESC/EAS Dyslipidaemia Guidelines; combination treatment; LDL cholesterol; triglycerides; lipid goals; high-risk; cardiovascular diseaselipid goalsbusiness.industryTask forceAnticholesteremic AgentsPCSK9Cholesterol LDL[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismAtherosclerosis2019 ESC/EAS Dyslipidaemia Guidelines3. Good health030104 developmental biologyDiabetes Mellitus Type 2Combination treatmentAtherosclerosiLDL cholesterolEuropean atherosclerosis societyKexinlipids (amino acids peptides and proteins)Proprotein Convertase 9Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessVery high risk
researchProduct

Imbalance Between Oxidative Stress and Growth Factors in Human High Myopia.

2020

Este artículo se encuentra disponible en la siguiente URL: https://www.frontiersin.org/articles/10.3389/fphys.2020.00463/full Myopia is one of the commonest eye pathologies that could affect 2.56 billion people by 2020. Today high myopia is a leading cause of blindness worldwide due to associated ocular illness. Nevertheless, the cellular bases for these diseases to develop are unclear in many areas. We conducted a prospective study of oxidative stress and growth factors in human myopic and non myopic eyes in an attempt to increase our understanding of the underlying physiopathological conditions to adequately early diagnose, prevent and treat the retina problem that derives from myopia. Aq…

0301 basic medicinemedicine.medical_specialtygenetic structuresNitratos.PhysiologyVEGF receptorsCrecimiento - Factores.Affect (psychology)medicine.disease_causelcsh:Physiology03 medical and health sciencesElisa kit0302 clinical medicineCataractsPhysiology (medical)OphthalmologyMedicineoxidative stresstotal nitratesNitrates.HGFProspective cohort studyhigh myopiaDioptreOriginal ResearchEstrés oxidativo.biologylcsh:QP1-981business.industryMiopía.High myopiaTACGrowth factors.medicine.diseaseVEGFeye diseasesOxidative stress.030104 developmental biology030221 ophthalmology & optometrybiology.proteinsense organsbusinessMyopia.Oxidative stressFrontiers in physiology
researchProduct

Update and guidance on management of myopia : European Society of Ophthalmology in cooperation with International Myopia Institute

2021

The prevalence of myopia is increasing extensively worldwide. The number of people with myopia in 2020 is predicted to be 2.6 billion globally, which is expected to rise up to 4.9 billion by 2050, unless preventive actions and interventions are taken. The number of individuals with high myopia is also increasing substantially and pathological myopia is predicted to become the most common cause of irreversible vision impairment and blindness worldwide and also in Europe. These prevalence estimates indicate the importance of reducing the burden of myopia by means of myopia control interventions to prevent myopia onset and to slow down myopia progression. Due to the urgency of the situation, t…

0301 basic medicinemedicine.medical_specialtygenetic structuresmedicine.medical_treatmentatropinePsychological interventionReviewsorthokeratologylikinäköisyyspreventive medicineehkäisevä lääketiede03 medical and health sciences0302 clinical medicineOphthalmologynäkövammatEpidemiologyMyopiaPrevalenceMedicineHumansmyopiaPreventive healthcareBlindnessbusiness.industrypathologic myopiaPathological myopiaOrthokeratologyHigh myopiaTreatment optionsGeneral Medicinemedicine.diseasetime spent outdoorsmyopia reduction interventionsMyopia Degenerative/epidemiologyeye diseasesOphthalmology030104 developmental biologyMyopia Degenerativesilmätaudit030221 ophthalmology & optometryDisease Progressionsense organsbusinessOrthokeratologic Proceduresblindnesssokeus
researchProduct

The genomic sequence of Exiguobacterium chiriqhucha str. N139 reveals a species that thrives in cold waters and extreme environmental conditions

2017

We report the genome sequence of Exiguobacterium chiriqhucha str. N139, isolated from a high-altitude Andean lake. Comparative genomic analyses of the Exiguobacterium genomes available suggest that our strain belongs to the same species as the previously reported E. pavilionensis str. RW-2 and Exiguobacterium str. GIC 31. We describe this species and propose the chiriqhucha name to group them. ‘Chiri qhucha’ in Quechua means ‘cold lake’, which is a common origin of these three cosmopolitan Exiguobacteria. The 2,952,588-bp E. chiriqhucha str. N139 genome contains one chromosome and three megaplasmids. The genome analysis of the Andean strain suggests the presence of enzymes that confer E. ch…

0301 basic medicinemegaplasmidBioinformaticsOtras Ciencias Biológicas[SDV]Life Sciences [q-bio]Microbial metabolismBiodiversitylcsh:MedicineGenomicsTryptophan biosynthesisMicrobiology High altitude Andean lakesBiologySubjects BiochemistryGenomeBiochemistryMicrobiologyGeneral Biochemistry Genetics and Molecular BiologyCiencias Biológicas//purl.org/becyt/ford/1 [https]03 medical and health sciencesExtremophilesArsenic resistanceExiguobacteriumBotanyExtremophile//purl.org/becyt/ford/1.6 [https]genome2. Zero hungerWhole genome sequencingGeneticsGeneral Neurosciencelcsh:RGeneral MedicineBiodiversityGenomicsMetals or metalloidsExiguobacteriumbiology.organism_classificationHigh altitude Andean lakes030104 developmental biologyMicrobial population biology13. Climate actionUV resistanceBacterial metabolismGeneral Agricultural and Biological SciencesCIENCIAS NATURALES Y EXACTAS
researchProduct

High intensity aquatic exercise or daily physical activity for maintaining fat mass and walking ability for postmenopausal women with knee osteoarthr…

2016

030203 arthritis & rheumatology030222 orthopedicsmedicine.medical_specialtyPostmenopausal womenbusiness.industryHigh intensityPhysical activityAquatic exerciseBiomedical EngineeringOsteoarthritismedicine.diseaseFat mass03 medical and health sciences0302 clinical medicineRheumatologyPhysical therapymedicineOrthopedics and Sports MedicinebusinessOsteoarthritis and Cartilage
researchProduct

Generation of TCR-engineered reference cell samples to control T-cell assay performance

2020

In vitro cellular assays analyzing antigen-specific T cells are characterized by their high complexity and require controlled conditions to lower experimental variations. Without standard cellular reagents, it is difficult to compare results over time and across institutions. To overcome this problem, a simple and robust technology was developed to generate TCR-engineered reference samples (TERS) containing defined numbers of antigen-specific T cells. Utilization of TERS enables performance control of three main T-cell assays: MHC-peptide multimer staining, IFN-gamma ELISpot and cytokine flow cytometry. TERS continuously deliver stable results and can be stored for longer periods of time. H…

0303 health sciencesChemistryElectroporationELISPOTT cell030303 biophysicsT-cell receptorfood and beveragesReference cellPerformance control03 medical and health sciencesmedicine.anatomical_structureHigh complexitymedicineCytokine flow cytometryBiomedical engineering
researchProduct

Influence of sugar and fat contents on preference for cream cheese: A preliminary study

1993

Abstract In order to assess the importance of fat and sugar in acceptability of semi-solid French cream cheese, 30 subjects gave a hedonic judgement, after consumption, for three formulations (150 g) varying in fat content which they were required to sweeten and for nine small previously sweetened samples (30 g). Subjects participated in five laboratory meals, cream cheese being the third part of a meal. After this period, the subjects filled out a questionnaire measuring attitudes, beliefs and intention of behaviour with regard to consumption of cream cheese. Sugar level had no significant effect on the hedonic judgement. However, the subjects added less sugar in the high fat cream cheese …

0303 health sciencesMealNutrition and Dietetics030309 nutrition & dieteticsbusiness.industryFat contentdigestive oral and skin physiologyfood and beverages04 agricultural and veterinary sciences[SDV.IDA] Life Sciences [q-bio]/Food engineeringCream cheese040401 food sciencePreference03 medical and health sciences0404 agricultural biotechnologyfood[SDV.IDA]Life Sciences [q-bio]/Food engineeringHigh fatMedicineFood sciencefood.cheeseSugarbusinessComputingMilieux_MISCELLANEOUSFood ScienceFood Quality and Preference
researchProduct